Previously recorded as Roche Nimblegen, Inc. (to 2017)
Previously recorded as Genia Technologies, Inc. (to 2020)
366 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Roche Sequencing Solutions, Inc. portfolio ends in Jun 2028, and more of its terms end in 2037 (69) than in any other year. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
23
Ending by 2030
Jun 2028
Next term end
157
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2032 · Medium confidence
Also notable
Ends Sep 2030 · High confidence
Also notable
Ends Feb 2030 · High confidence
Also notable
Ends no later than Jan 2035 · Medium confidence
Also notable
Ends Jan 2029 · High confidence
Also notable
Ends Dec 2034 · High confidence
Also notable
Ends Jun 2035 · High confidence
Also notable
Ends Feb 2036 · High confidence
Methods of Identifying Multiple Epitopes in Cells
US 10,144,950
The most cited patent in this portfolio, cited by 241 later US patents, top 1% of utility patents granted in 2018 in our data. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Systems and Methods for Characterizing a Molecule
US 8,324,914
Cited by 160 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Systems and Methods for Forming a Nanopore in a Lipid Bilayer
US 9,605,307
Cited by 74 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Increasing Dynamic Range for Identifying Multiple Epitopes in Cells
US 10,174,310
Cited by 231 later US patents, top 1% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
High Throughput Nucleic Acid Sequencing by Expansion
US 7,939,259
Cited by 188 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Nucleic Acid Sequencing Using Tags
US 9,605,309
Cited by 77 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Nanopore-Based Sequencing with Varying Voltage Stimulus
US 9,557,294
Cited by 29 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Polymerase Variants and Uses Thereof
US 10,526,588
Cited by 17 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 8 fees due Jan 4 to 30, 2027 · next Jan 4
- 13 fees due Feb 6 to 28, 2027 · next Feb 6
- 9 fees due Mar 1 to 26, 2027 · next Mar 1
- 11 fees due Apr 1 to 30, 2027 · next Apr 1
- 5 fees due May 5 to 21, 2027 · next May 5
- 1 fee due Jun 19, 2027The maintenance fee for Two-Way Pump Selectable Valve and Bypass Waste Channel (US 11,846,281) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 7 fees due Jul 2 to 30, 2027 · next Jul 2
- 4 fees due Aug 6 to 27, 2027 · next Aug 6
- 12 fees due Sep 3 to 26, 2027 · next Sep 3
- 7 fees due Oct 2 to 30, 2027 · next Oct 2
- 7 fees due Nov 5 to 21, 2027 · next Nov 5
Recent changes
- 8 of the patents on this record were granted since Aug 24, 2026
What they patent
The largest of its 157 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods of Identifying Multiple Epitopes in Cells | 25 in force | to May 2034 |
| Systems and Methods for Forming a Nanopore in a Lipid Bilayer | 12 in force | to Oct 2031 |
| Method for Inline Bilayer Capacitance Monitoring | 7 in force | to Mar 2036 |
| Nanopore-Based Sequencing with Varying Voltage Stimulus | 6 in force | to Oct 2036 |
| Polymerase Variants | 6 in force | to Mar 2036 |
| System for Communicating Information from an Array of Sensors | 6 in force | to Mar 2033 |
| Molded Flow Channel | 5 in force | to Jun 2038 |
| Nanopore Arrays | 5 in force | to Aug 2035 |
| Nucleic Acid Sequencing Using Tags | 5 in force | to Dec 2034 |
| Sensor Circuit for Controlling, Detecting, and Measuring a Molecular Complex | 5 in force | to Feb 2033 |
| Nanopore-Based Single DNA Molecule Characterization, Identification and Isolation Using Speed Bumps | 5 in force | to Jan 2033 |
| Noise Shielding Techniques for Ultra Low Current Measurements in Biochemical Applications | 5 in force | to Feb 2032 |
| Immuno-Pete | 4 in force | to Mar 2040 |
| Epitachophoresis Device | 4 in force | to Aug 2038 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,324,360 | High Throughput Nucleic Acid Sequencing by Expansion In force · High confidence | In force | High confidence | |
| US 8,349,565 | High Throughput Nucleic Acid Sequencing by Expansion In force · High confidence | In force | High confidence | |
| US 9,920,386 | High Throughput Nucleic Acid Sequencing by Expansion In force · Medium confidence | In force | Medium confidence | |
| US 10,900,068 | Methods and Systems for Solution Based Sequence Enrichment In force · Low confidence | In force | Low confidence | |
| US 7,939,259 | High Throughput Nucleic Acid Sequencing by Expansion In force · High confidence | In force | High confidence | |
| US 9,790,543 | Methods and Systems for Solution Based Sequence Enrichment In force · Low confidence | In force | Low confidence | |
| US 8,461,854 | Systems and Methods for Characterizing a Molecule In force · High confidence | In force | High confidence | |
| US 9,377,437 | Systems and Methods for Characterizing a Molecule In force · High confidence | In force | High confidence | |
| US 9,605,307 | Systems and Methods for Forming a Nanopore in a Lipid Bilayer In force · High confidence | In force | High confidence | |
| US 9,617,595 | Systems and Methods for Assembling a Lipid Bilayer on a Substantially Planar Solid Surface In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 366: 7 patents in force now held by others · 7 patents ended · 138 applications pending · 71 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.